January 12, 2021 – A change in evidence-based guidelines for vasectomy may have led to a reduction in the number of follow-up tests to confirm the procedure was successful, reports a study in Urology Practice®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Originally published in 2012, and then updated in 2015, the AUA clinical guideline could significantly reduce the number of men undergoing multiple postvasectomy semen analyses (PVSAs) to confirm it’s safe to stop using other methods of birth control, according to new research by Tony Chen, MD, of University of Washington, Seattle, and colleagues. Dr. Chen comments: “Our study of nearly 90,000 patients strongly suggests that men underwent fewer repeat PVSAs after the guideline update, potentially avoiding many unnecessary tests and reducing costs.”
One-third reduction in repeat testing after vasectomy
Vasectomy is a safe and highly effective method of permanent contraception in men, performed about 500,000 times per year in the United States. Follow-up PVSA tests, done two to four months after the procedure, are recommended to confirm that vasectomy was successful. Previous standard of practice called for two consecutive PVSAs showing no measurable sperm count (azoospermia).
However, there were concerns this previous practice may have been inconvenient for patients while leading to increased costs. Meanwhile, new evidence suggested that less-stringent criteria might be just as effective in confirming the success of vasectomy. The 2012 AUA guidelines called for just one PVSA showing no or only rare, nonmoving (nonmotile) sperm.
Dr. Chen and colleagues used a national insurance claims database to analyze more than 87,000 men who underwent vasectomy and had at least one claim for follow-up PVSA between 2007 and 2015. Data from before and after the 2012 AUA guideline update were used to see if the new recommendation coincided with a reduced number of PVSAs performed.
The percentage of men undergoing repeat PVSAs decreased after the guideline update: from 39 percent in 2007-12 to 31 percent in 2013-15. After adjustment for other factors, the percentage of vasectomy patients undergoing repeat PVSA decreased by about one-third (odds ratio 0.68).
There was also a small, but significant reduction in the percentage of men undergoing three or more PVSAs (odds ratio 0.82). Men who had only one PVSA had longer average times to the first follow-up test. That was consistent with an AUA recommendation to wait within a range of 8 to 16 weeks before the first PVSA.
Dr. Chen and colleagues note some important limitations of their study. Many urologists “bundle” the vasectomy procedure and follow-up testing, meaning there’s no new insurance claim when PVSA is performed. Nearly 80 percent of vasectomy patients in the database had no separate claims for PVSA.
“Although we can’t prove that the reduction in repeat PVSAs resulted directly from the new guidelines, the results are strongly suggestive that they had an impact,” Dr. Chen adds. “If the one-third reduction we found is correct and applicable to the male population at large, that will mean a significant reduction in costs and inconvenience related to follow-up testing for the many thousands of men who undergo vasectomy each year.” The researchers call for further studies “to improve adherence to clinical guidelines and optimize value for this commonly performed procedure.”
DOI: 10.1097/UPJ.0000000000000196
###
About Urology Practice
An Official Journal of the American Urological Association (AUA), Urology Practice focuses on clinical trends, challenges and practice applications in the four areas of Business, Health Policy, the Specialty and Patient Care. Information that can be used in everyday practice will be provided to the urology community via peer-reviewed clinical practice articles (including best practices, reviews, clinical guidelines, select clinical trials, editorials and white papers), “research letters” (brief original studies with an important clinical message), the business of the practice of urology, urology health policy issues, urology education and training, as well as content for urology care team members.
About the American Urological Association
Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has nearly 24,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health care policy. To learn more about the AUA visit: www.auanet.org.
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2019 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students with advanced clinical decision support, learning and research and clinical intelligence. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.
